Enantioselective Catalytic Transformations of Barbituric Acid Derivatives

Total Page:16

File Type:pdf, Size:1020Kb

Enantioselective Catalytic Transformations of Barbituric Acid Derivatives catalysts Review Enantioselective Catalytic Transformations of Barbituric Acid Derivatives Claire Segovia, Arthur Lebrêne , Vincent Levacher , Sylvain Oudeyer and Jean-François Brière * Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France; [email protected] (C.S.); [email protected] (A.L.); [email protected] (V.L.); [email protected] (S.O.) * Correspondence: [email protected]; Tel.: +33-235-522-464 Received: 20 December 2018; Accepted: 15 January 2019; Published: 1 February 2019 Abstract: Since the beginning of the 20th century, numerous research efforts made elegant use of barbituric acid derivatives as building blocks for the elaboration of more complex and useful molecules in the field of pharmaceutical chemistry and material sciences. However, the construction of chiral scaffolds by the catalytic enantioselective transformation of barbituric acid and derivatives has only emerged recently. The specific properties of these rather planar scaffolds, which also encompass either a high Brønsted acidity concerning the native barbituric acid or the marked electrophilic character of alkylidene barbituric acids, required specific developments to achieve efficient asymmetric processes. This review covers the enantioselective catalytic reactions developed for barbituric acid platforms using an organocatalytic and metal-based enantioselective sequences. These achievements currently allow several unique addition and annulation reactions towards the construction of high valued chiral heterocycles from barbituric acid derivatives along with innovative enantioselective developments. Keywords: organocatalysis; asymmetric synthesis; barbituric acid; alkylidene barbituric acid; metal based-catalysis; cycloaddition; annulation reaction 1. Introduction 1.1. Context Barbituric acid 1, namely 2,4,6-(lH,3H,5H)-pyrimidinetrione, and derivatives are fascinating building blocks in organic synthesis (Figure1). This story dates back to 1894 when von Baeyer reported on the preparation of barbituric acid [1]. Later, in 1903, Fisher and von Mering highlighted the pharmacological properties of 5,5-diethyl barbituric acid, the so-called barbital, as a potent hypnotic agent [2]. Ever since, barbituric acid derivatives served as starting materials for the elaboration of thousands of complex architectures useful in medicinal chemistry, a field of research covered by several exhaustive reviews [3–6]. Selected examples of bioactive compounds in this series are depicted in Figure1, which highlights scaffolds that possess, at least, one stereogenic center or a tetrasubstituted carbon as a source of chemical diversity and structural complexity. Phenobarbital, involved in the treatment of certain types of epilepsy, derived from the original barbital but displays two different substituents at C-5 position (Figure1a) [ 7]. The opportunity afforded by the double functionalization of the C-5 position of barbituric acid allowed the construction of several spiro-compounds and, thus, more rigid architectures highlighted by the development of nucleotide mimics [8], inhibitor of matrix metalloproteinases (MMP) [9] and anticancer agents [10], for example (Figure1b–d) [ 11,12]. On the other hand, the synthesis of fused-bicycle derivatives led to ingredients possessing either Catalysts 2019, 9, 131; doi:10.3390/catal9020131 www.mdpi.com/journal/catalysts Catalysts 2019, 9, 131 2 of 27 antidiabetic [13] or antituberculosis properties (Figure1e–f) [ 14]. Besides medicinal chemistry, theCatalysts photophysical 2018, 8, x FOR properties PEER REVIEW of barbituric acid derivatives were exploited in colorimetric or heat2 of 30 detection [15], and provided promising dyes or fluorogenic probes to name a few [16,17]. 45 46 47 FigureFigure 1. Barbituric 1. Barbituric acid acid scaffolds scaffolds within within bioactive bioactive architectures. architectures. 48 TheThe versatile versatile properties properties of productsof products obtained obtained from from barbituric barbituric acid acid elicited elicited the the motivation motivation of of 49 organicorganic chemists chemists to to explore explore its its chemistry chemistry [3 ,4[3,4,6],,6], and and more more recent recent evolutions evolutions have have met met the the 50 developmentdevelopment of efficientof efficient multicomponent multicomponent reactions reactions (MCR) (MCR) [16,18 [16,18].]. Despite Despite great great synthetic synthetic advances advances in 51 thisin field this of research,field of theresearch, use of diastereoselectivethe use of diastere sequencesoselective or separation sequences techniques or separation (crystallization techniques or 52 chromatography)(crystallization of or racemic chromatography) mixtures were of required racemic for mixtures the elaboration were required of enantiopure for the architectures elaboration of of 53 chiralenantiopure bioactive architectures compounds asof chiral depicted bioactive in Figure compounds1[ 19]. At as thedepicted end of in the Figure 1990s, 1 [19]. the pioneeringAt the end of 54 researchthe 1990s, of Brunner’s the pioneering group, onresearch the palladium-catalyzed of Brunner’s group, enantioselective on the palladium-catalyzed alkylation of barbituric enantioselective acid 55 derivativesalkylation have of barbituric shed light acid on thederiva potentialtives have of this shed starting light on material the potential in asymmetric of this starting synthesis material while in 56 pointingasymmetric out challenges, synthesis which while have pointing to be out overcome challenges, with thiswhich unique have architecture to be overcome [20–23 with]. This this review unique 57 intendsarchitecture to cover [20–23]. the literature This review dealing intends with the to enantioselective cover the literature catalytic dealing transformations with the enantioselective of barbituric 58 acidcatalytic derivatives, transformations an exercise of which barbituric is unprecedented acid derivatives, to the an best exercise of our which knowledge. is unprecedented The literature to the 59 concerningbest of our the knowledge. enantioselective The literature transformations concerning of barbituricthe enantioselective acid and alkylidenetransformations barbituric of barbituric acid 60 derivativesacid and willalkylidene be discussed barbituric separately, acid derivatives to focus on specificwill be typesdiscussed of reactions separately, developed to focus for on a givenspecific 61 barbituratetypes of reactions structure. developed To give a flavor for a given of the barbiturate uniqueness structure. of barbituric To acidgive compounds,a flavor of the its uniqueness properties of 62 willbarbituric first be introduced. acid compounds, its properties will first be introduced. 63 1.2.1.2. Properties Properties of Barbituricof barbituric Acid acid Derivatives derivatives 64 To gainTo gain insight insight into into the reactivitythe reactivity of barbituric of barbituric acid acid derivatives, derivatives, the unique the unique chemical chemical properties properties of 65 theseof these molecules molecules have have to be to taken be taken into account.into account. As shownAs shown in Figure in Figure2a, barbituric2a, barbituric acid acid1 displays 1 displays a a 66 ratherrather low low pK apKvaluea value (pK (pa K=a 8.4= 8.4 in in DMSO) DMSO) [24 [24]] lying lying just just above above Meldrum’s Meldrum’s acid acid2 well-known 2 well-known for for its its 67 remarkableremarkable acidity acidity (pK (pa =Ka 7.03 = 7.03 in DMSO)in DMSO) [25 [25,26].,26]. Consequently, Consequently, barbituric barbituric acid acid1 and 1 and derivatives derivatives will will 68 be much more prone to deprotonation by soft bases than dimedone 3 or non-cyclic homologues, 69 such as malonate 4, for instance. However, direct correlation between the pKa value and the 70 nucleophilic behavior is not always feasible [27]. 71 Catalysts 2019, 9, 131 3 of 27 Catalystsbe much 2018, more 8, x FOR prone PEER to REVIEW deprotonation by soft bases than dimedone 3 or non-cyclic homologues,3 suchof 30 as malonate 4, for instance. However, direct correlation between the pKa value and the nucleophilic behavior is not always feasible [27]. 72 73 74 FigureFigure 2. 2.PropertiesProperties of ofbarbituric barbituric acid acid derivatives. derivatives. (a) (Aciditya) Acidity given given in inDMSO. DMSO. (b) ( bNucleophilic) Nucleophilic 75 reactivityreactivity parameters parameters of ofanions. anions. 76 In In2017, 2017, Spange Spange and and co-workers co-workers embarked embarked on on the the insightful insightful evaluation evaluation of ofthe the kinetics kinetics of of 77 derivativesderivatives of ofbarbiturate barbiturate acid acid anions anions thanks thanks to tothe the reaction reaction with with specific specific electrophiles, electrophiles, such such as as 78 benzhydryliumbenzhydrylium cations cations and and Michael Michael acceptors acceptors [28]. [28 Then,]. Then, the the so-called so-called nucleophilicity nucleophilicity parameter parameter N N 79 andand the the corresponding corresponding nucleophile-sp nucleophile-specificecific susceptibility susceptibility parameter parameter sNs ofN ofbarbiturate barbiturate anions anions 1’ 1’couldcould 80 bebe determined determined and and compared compared to torelated related 1,3-dicarbonyl 1,3-dicarbonyl anions anions 2’-2’4’- 4(Figure’ (Figure 2b)2b) [27]. [ 27 ].Barbituric Barbituric acid acid 81 anionanion 1’ 1’featuresfeatures a nucleophilic a nucleophilic character character
Recommended publications
  • Oral Fluid Drug Test Package Insert
    Marijuana (THC) 11-nor-Δ9-THC-9 COOH 4 MTD: Methadone is a synthetic analgesic drug originally used for the Oral Fluid Drug Test treatment of narcotic addiction. In addition to use as a narcotic agonist, methadone is being used more frequently as a pain management agent. The Marijuana (THC) Δ9-THC 50 Package Insert psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Based on the saliva/plasma ratio calculated over Package insert for testing of the following drugs: > 0.02 % Alcohol (ALC) Alcohol salivary pH ranges of 6.4-7.6 for therapeutic or recreational doses of Amphetamine,Cocaine,Marijuana,Methamphetamine,Opiate,Methadone, B.A.C methadone, a cut-off <50 ng/mL is suggested. Due to this recommendation, Phencyclidine,Oxycodone,Benzodiazepine,Buprenorphine,Barbiturates, the cut-off level of the methadone test was calibrated to 30 ng/mL. Cotinine,EDDP,MDMA,6-MAM,Propoxyphene ,Fentanyl,ETG and Alcohol Tramadol(TRA) 50 Tramadol PCP: Phencyclidine is a hallucinogen and, can be detected in oral fluid as a INTENDED USE & SUMMARY result of the exchange of the drug between the circulatory system and the oral cavity.5 Fentanyl(FEN) 10 The Oral Fluid Drug And Alcohol Test is intended for screening for the Norfentanyl presence of drugs and alcohol and their metabolites in oral fluid. For professional in vitro diagnostic use only. OXY: Oxycodone is a semi-synthetic opioid with a structural similarity to Ethyl codeine. The drug is manufactured by modifying thebaine, an alkaloid found in 150 The Oral Fluid Pipette Test is a lateral flow chromatographic immunoassay for Glucuronide(ETG) the opium poppy.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062165 B. Purpose for Submission: New device C. Measurand: Barbiturates D. Type of Test: Qualitative and semi-quantitative enzyme immunoassay E. Applicant: Ortho-Clinical Diagnostics, Inc. F. Proprietary and Established Names: VITROS Chemistry Products BARB Reagent VITROS Chemistry Products Calibrator 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, III, IV and V G. Regulatory Information: 1. Regulation section: 21 CFR 862.3150, Barbiturates test system 21 CFR 862.3200, Clinical Toxicology Calibrator 21 CFR 862.3180, Clinical Toxicology Control 2. Classification: Class II, (reagent, calibrator) Class I, reserved (control) 3. Product code: DIS, DLJ and DIF 4. Panel: Toxicology (91) 1 H. Intended Use: 1. Intended use(s): See Indications for use. 2. Indication(s) for use: VITROS Chemistry Products BARB Reagent: For in vitro diagnostic use only. VITROS Chemistry Products BARB Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi- quantitative or qualitative determination of barbiturates (BARB) in human urine using a cutoff of 200 ng/mL or 300 ng/mL. Measurements obtained with the VITROS BARB method are used in the diagnosis and treatment of barbiturates use or overdose. The VITROS Chemistry Products BARB assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result with this assay. Gas Chromatograpy/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • September 25, 2020 Guangzhou Wondfo Biotech Co., Ltd. Joe Shia
    September 25, 2020 Guangzhou Wondfo Biotech Co., Ltd. ℅ Joe Shia Manager LSI International 504 E Diamond Ave., Suite I Gaithersburg, MD 20877 Re: K202567 Trade/Device Name: Wondfo T-Dip® Multi-Drug Urine Test Panel Wondfo T-Dip® Multi-Drug Urine Test Panel Rx Regulation Number: 21 CFR 862.3100 Regulation Name: Amphetamine test system Regulatory Class: Class II Product Code: NFT, NGL, PTH, NFV, NFY, PTG, NGG, LCM, QBF, QAW, NFW Dated: September 2, 2020 Received: September 4, 2020 Dear Joe Shia: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • 89 Abstract Biological Activity and Analytical
    BIOLOGICAL ACTIVITY AND ANALYTICAL CHARACTERIZATION OF BARBITURIC ACID Vijaya Laxmi S, Janardhan B, Rajitha B ijcrr Vol 04 issue 07 Department of Chemistry, National Institute of Technology, Warangal Category: Review Received on:12/12/11 E-mail of Corresponding Author: [email protected] Revised on:15/01/12 Accepted on:28/02/12 ABSTRACT Earlier literature reports imply that this scaffold is having activity on central nervous system. According to the present studies it has become an attractive target for the development of drugs, which hold variety of biological activities. Derivatives of barbituric acid have attracted the attention of researchers in synthetic organic chemistry, as well as medicinal chemistry, for a long time as a result of their exceptionally diverse biological activity. Present review highlights the importance of the barbituric acid in the present context. ____________________________________________________________________________________ Keywords: Barbituric acid, Biological activity, biological activities that stand apart from Spectral studies, X-ray Crystallography, Dye previous medical utilization of barbituric acid properties. derivatives.4 However it is a precursor to barbituric acid derivatives widely been used in 1 INTRODUCTION the manufacturing of plastics,5 textiles,6 Barbituric acid (BA) is documented as the parent polymers,7 and pharmaceuticals,8-9 dental compound of the barbiturate drugs. (Fig.1). It is materials,10 water thinned or oil-based inks,11 used in the production of riboflavin, Nembutal, and as polymerization catalysts.12 In view of the and Phenobarbital.1-2 This class of compounds above observations it is worthwhile to make a has been extensively used in medical and brief review on it.
    [Show full text]
  • ECO Cup One Step Drug Test Forensic Insert
    paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 unconsciousness. hours following use, and the drug has a half-life of 4-24 hours in the body. About 30% of Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base Amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated smoking. It is excreted in the urine in a short time primarily as Benzoylecgonine. 1.2 and deaminated derivatives. Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than 2 The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Amphetamine cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure. in urine exceeds 1,000 ng/mL. This is the suggested screening cut-off for positive specimens The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Benzoylecgonine set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).3 in urine exceeds 300 ng/mL. This is the suggested screening cut-off for positive specimens set by One Step Drug Test the Substance Abuse and Mental Health Services Administration (SAMHSA, USA). 3 Package Insert for Multi Drug Screen Test Cup AMPHETAMINE (AMP 500) COCAINE (COC 150) This Instruction Sheet is for testing of any combination of the following drugs: See AMPHETAMINE (AMP 1000) for the summary. See COCAINE (COC 300) for the summary. AMP/BAR/BZO/BUP/COC/THC/MTD/mAMP/MDMA/MOR/OPI/OXY/PCP/PPX/TCA/EDDP/6-ACM/ETG The ECO CUP™ One Step Drug Test yields a positive result when the concentration of The ECO CUP™ One Step Drug Test yields a positive result when the concentration of Including Adulterant Tests (Specimen Validity Tests) for: Amphetamine in urine exceeds 500 ng/mL.
    [Show full text]
  • 220-D100 Toxicology Procedures Manual
    Department of Forensic Science COPYRIGHT © 2021 TOXICOLOGYVIRGINIA PROCEDURESDEPARTMENT MANUAL OF FORENSIC SCIENCE 220-D100 Toxicology Procedures Manual Qualtrax ID: 2816 Issued by Toxicology Program Manager UNCONTROLLED Qualtrax Revision 20 Issue Date: 27-July-2021 Page 1 of 246 COPY Table of Contents TABLE OF CONTENTS 1 Introduction 1.1 Introduction 1.2 Toxicology Analytical Schemes Introduction 1.3 Toxicology Analytical Schemes 2 Toxicology Quality Guidelines 2.1 Summary 2.2 Guidelines for Confirming Positive Results 2.3 Guidelines for Batch Analysis 2.4 Quality Assurance and Quality Control 2.5 Chromatographic and Mass Spectral Quality Control 2.6 Criteria for Reporting Toxicology Case Results 2.7 Report Wording 2.8 Guidelines forCOPYRIGHT Method Validation and Verification © 2021 3 Sampling Procedure 4 Evidence Handling and Storage VIRGINIA 4.1 Evidence Submission 4.2 Evidence Receipt DEPARTMENT 4.3 Storage of Toxicology Biological Evidence 4.4 DUI Evidence Handling OF 5 Estimation of the Uncertainty of Measurement FORENSIC SCIENCE 5.1 Scope 5.2 Documentation 5.3 Uncertainty of Measurement 5.4 Reporting the Estimated Uncertainty of Measurement 5.5 Measurement Traceability 5.6 References 6 Quality Assurance 6.1 Introduction 6.2 Reagents 6.3 Preparation of Blank Blood 6.4 Reference Material 6.5 Reference Collections 6.6 Balances 6.7 pH Meters 6.8 Pipettes 6.9 Refrigerators/Freezers 6.10 Heat Blocks 6.11 Evaporators 6.12 Centrifuges 6.13 Thermometers 6.14 Incubators (Ovens) 6.15 Fume Hoods and Biological Safety Cabinets 6.16 UV-VIS
    [Show full text]
  • The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest
    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 5-21-2004 The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest Donna Neumann University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation Neumann, Donna, "The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest" (2004). University of New Orleans Theses and Dissertations. 1040. https://scholarworks.uno.edu/td/1040 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. THE DESIGN AND SYNTHESIS OF NOVEL BARBITURATES OF PHARMACEUTICAL INTEREST A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Donna M. Neumann B. A. University of New Orleans, 2000 May 2004 Dedicated to: My daughter, Madeline Megan Jenkins ii ACKNOWLEDGEMENTS I would like to express my utmost gratitude to my advisor, Professor Branko S.
    [Show full text]
  • Wo 2009/074533 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 18 June 2009 (18.06.2009) WO 2009/074533 A2 (51) International Patent Classification: (74) Common Representative: CIBA HOLDING INC.; C09B 67/14 (2006.01) C09B 57/04 (2006.01) Patent Department,, Klybeckstrasse 141, CH-4057 Basel C09B 67/20 (2006.01) C08K 5/00 (2006.01) (CH). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/EP2008/06701 1 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, 8 December 2008 (08.12.2008) CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (25) Filing Language: English EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (26) Publication Language: English LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, (30) Priority Data: MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, 07122749.0 10 December 2007 (10.12.2007) EP RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, 08157426.1 2 June 2008 (02.06.2008) EP TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant (for all designated States except US): CIBA ZW HOLDING INC. [CWCH]; Klybeckstrasse 141, CH-4057 (84) Designated States (unless otherwise indicated, for every Basel (CH).
    [Show full text]
  • Reactions of Carbanions with Michael Acceptors and Electron-Deficient Arenes: Quantifying Polar Organic Reactivity
    Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Reactions of Carbanions with Michael Acceptors and Electron-deficient Arenes: Quantifying Polar Organic Reactivity Dipl. Chem. Florian Seeliger aus Hamburg 2008 Erklärung Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung vom 29. Januar 1998 von Herrn Prof. Dr. Herbert Mayr betreut. Ehrenwörtliche Versicherung Diese Dissertation wurde selbständig und ohne unerlaubte Hilfe erarbeitet. München, 13.03.2008 ……..…………………………... Florian Seeliger Dissertation eingereicht am 13.03.2008 1.Gutachter Prof. Dr. Herbert Mayr 2.Gutachter Prof. Dr. Hendrik Zipse Mündliche Prüfung am 24.04.2008 Für Birgit Danksagung Ich möchte mich an dieser Stelle ganz herzlich bei Herrn Prof. Dr. Herbert Mayr für seine herausragende und beispielhafte Betreuung während der Durchführung meiner Arbeit, die interessante Themenstellung und seine stete Hilfs- und Diskussionsbereitschaft bedanken. Weiterhin gilt mein Dank Herrn Prof. Dr. Mieczyslaw Makosza, der es mir ermöglichte, für 2 Monate in Warschau zu forschen und Prof. Dr. Hendrik Zipse, der mir als Ratgeber für die quantenchemischen Rechnungen hilfreich zur Seite stand. Den Mitgliedern des Arbeitskreises danke ich für ein äußerst angenehmes Arbeitsklima mit vielen abwechslungsreichen Diskussionen über Chemie und andere Dinge. Meinen Laborkollegen Oliver Kaumanns, Heike Schaller, Markus Horn und Erik Breuer sei für ihre Hilfsbereitschaft und das tolle Arbeitsklima besonders
    [Show full text]
  • Chem 263 Dec 2, 2010 Note That Another Carbon Dioxide Derivative Is
    Chem 263 Dec 2, 2010 Note that another carbon dioxide derivative is a urethane. Some derivatives of these may be polymerized to form polyurethane. O O NH2 The alkylation product of dimethyl malonate shown last class can be alkylated again, as there is another alpha proton present. O O O O O 1) Base H2O, HCl H3CO OCH3 H3CO OCH3 HO heat H 2) CH3CH2I O CO2 H2N NH2 2 CH3OH O HN NH O O The product from this reaction, dimethyl 2,2-diethylmalonate, can be used to perform other reactions as shown above. Dimethyl 2,2-diethylmalonate can be treated with base or acid and water to form a dicarboxylic acid (hydrolysis), which can react further upon heating to lose carbon dioxide, as shown in the figure below. Alternately, dimethyl 2,2-diethylmalonate can react with urea to form barbital (diethyl barbiturate). O O O O 1) NaOH H CO OCH HO OH 3 3 2) HCl heat O OH OH H OH transfer 2-ethylbutyric acid Upon heating (denoted by the triangle), the dicarboxylic acid loses one of its carboxylic groups (CO2). This process is called decarboxylation. The product from this step is an enol. Upon treating with acid, we get a substituted acetic acid, specifically 2-ethylbutyric acid as the product. Dimethyl 2,2-diethylmalonate can also be used as a synthetic precursor for drugs. O O O O NH NH + H3CO OCH3 (heat) H2N NH2 urea O O Barbital Barbital (or diethyl barbiturate) belongs to a class of drugs called barbiturates. It is a sleeping pill used widely in the 1950’s.
    [Show full text]